Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV001578572 | SCV001547762 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2021-02-01 | criteria provided, single submitter | research | Frameshift variant (PVS1_very strong); the prevalence of the variant in affected individuals is significantly increased compared with the prevalence in controls (PS4_moderate); very low frequency in gnomAD v2.1.1 (PM2_moderate) |
Labcorp Genetics |
RCV001578572 | SCV004557584 | pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2023-11-17 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Lys218Glufs*45) in the GALNS gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GALNS are known to be pathogenic (PMID: 12442278). This variant is present in population databases (no rsID available, gnomAD 0.003%). This premature translational stop signal has been observed in individual(s) with mucopolysaccharidosis type IVA (PMID: 34387910). ClinVar contains an entry for this variant (Variation ID: 1048470). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV001578572 | SCV005641491 | likely pathogenic | Mucopolysaccharidosis, MPS-IV-A | 2024-01-05 | criteria provided, single submitter | clinical testing |